Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksBenchmark Holdings Regulatory News (BMK)

Share Price Information for Benchmark Holdings (BMK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 43.20
Bid: 44.10
Ask: 45.90
Change: -0.50 (-1.10%)
Spread: 1.80 (4.082%)
Open: 43.00
High: 43.20
Low: 43.00
Prev. Close: 45.50
BMK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Market Authorisation Update

3 May 2022 07:00

RNS Number : 9826J
Benchmark Holdings PLC
03 May 2022
 

3 May 2022

 

Benchmark Holdings plc

("Benchmark", the "Company" or the "Group")

 

Ectosan® Vet

Variation to Marketing Authorisation enabling a second use of treatment water

An important milestone towards optimal efficiency of Benchmark's transformational sea lice solution

 

Benchmark (LSE: BMK), the aquaculture biotechnology company, is pleased to announce that it has been granted a variation to its Marketing Authorisation ("MA") for Ectosan® Vet from the Norwegian Medicines Agency ("NoMA").

 

This variation to the MA enables the re-use of the treatment water for a second batch of fish, subject to water quality being maintained to the satisfaction of the prescribing veterinarian, therefore increasing the efficiency of treatments. This means a producer will be able to treat a salmon farm more efficiently with a solution that delivers more than 99% efficacy, promotes animal welfare, reduces mortality and protects the environment - driving sustainability in the industry.

 

This MA variation represents a further important step towards our goal of optimising the efficiency of our sea lice solution, and further trials are ongoing to support multiple re-use of treatment water.

 

 Trond Williksen, CEO, commented:

 

"We are very pleased to have been granted a variation to the Marketing Authorisation from the Norwegian Medicines Agency. This represents an important milestone for the Company and for the industry. Ectosan® Vet and CleanTreat® is a much needed solution for the industry which continues to show excellent results with efficacy above 99% as well as good operational efficiency. It is the first medicinal solution brought to the Norwegian market in over ten years which addresses one of the biggest challenges in salmon production, while improving animal welfare, reducing mortality and protecting the environment."

 

Enquiries:

 

Benchmark Holdings plc

Tel: 020 3696 0630

Trond Williksen, CEO

Septima Maguire, CFO

Ivonne Cantu, Investor Relations

 

 

 

Numis (Broker and NOMAD)

Tel: 020 7260 1000

James Black / Freddie Barnfield / Duncan Monteith

 

 

 

MHP

 

Katie Hunt/Charlie Protheroe/Fergal Bettridge-Boyd

Tel: 020 3128 8990

benchmark@mhpc.com

 

 

 

 

 

About Benchmark 

Benchmark is a market leading aquaculture biotechnology company. Benchmark's mission is to drive sustainability in aquaculture by delivering products and solutions in genetics, advanced nutrition and health which improve yield, growth and animal health and welfare.

Through a global footprint in 26 countries and a broad portfolio of products and solutions, Benchmark addresses the major aquaculture species - salmon, shrimp, sea bass and bream, and tilapia, in all the aquaculture regions around the world. Find out more at www.benchmarkplc.com

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
UPDBLLLBLELZBBL
Date   Source Headline
2nd May 20249:00 amRNSTotal Voting Rights
30th Apr 202410:55 amRNSForm 8.5 (EPT/RI) - Benchmark Holdings Plc
26th Apr 20244:18 pmRNSForm 8.3 - BENCHMARK HOLDINGS PLC
26th Apr 20241:54 pmRNSNotice of Q2 and Interim Results
25th Apr 20247:00 amRNSForm 8.3 - BENCHMARK HOLDINGS PLC
23rd Apr 202410:44 amRNSForm 8.5 (EPT/RI) - Benchmark Holdings Plc
23rd Apr 20247:00 amRNSRule 2.9 Announcement
22nd Apr 202410:42 amRNSForm 8.5 (EPT/RI) - Benchmark Holdings plc
19th Apr 20249:23 amRNSForm 8.5 (EPT/RI) - Benchmark Holdings plc
18th Apr 202410:37 amRNSForm 8.5 (EPT/RI) - Benchmark Holdings Plc
17th Apr 20244:13 pmRNSFORM 8.3 - BENCHMARK HOLDINGS PLC
17th Apr 202410:27 amRNSForm 8.5 (EPT/RI) - Benchmark Holdings Plc
16th Apr 20249:54 amRNSForm 8.5 (EPT/RI) - Benchmark Holdings Plc
11th Apr 202410:51 amRNSForm 8.5 (EPT/RI) - Benchmark Holdings Plc
8th Apr 202411:26 amRNSForm 8.5 (EPT/RI) - Benchmark Holdings Plc
5th Apr 202410:38 amRNSForm 8.5 (EPT/RI) - Benchmark Holdings plc
5th Apr 20249:23 amRNSForm 8.3 - Benchmark Holdings plc
28th Mar 202412:00 pmRNSTotal Voting Rights
22nd Mar 202411:51 amRNSForm 8.3 - Benchmark Holdings plc
22nd Mar 202410:52 amRNSForm 8.5 (EPT/RI) - Benchmark Holdings Plc
22nd Mar 202410:33 amRNSBENCHMARK Holdings PLC
21st Mar 20249:58 amRNSForm 8.3 - Benchmark Holdings plc
21st Mar 20247:00 amRNSBlock Listing Six Monthly Return
20th Mar 202411:28 amRNSForm 8.5 (EPT/RI) - Benchmark Holdings Plc
19th Mar 202410:01 amRNSForm 8.5 (EPT/RI) - Benchmark Holdings Plc
15th Mar 202411:13 amRNSForm 8.5 (EPT/RI) - Benchmark Holdings Plc
7th Mar 202411:26 amRNSForm 8.5 (EPT/RI) - Benchmark Holdings Plc
7th Mar 20247:00 amRNSRule 2.9 Announcement
6th Mar 202410:36 amRNSForm 8.5 (EPT/RI) - Benchmark Holdings Plc
5th Mar 202411:10 amRNSForm 8.5 (EPT/RI) - Benchmark Holdings plc
4th Mar 20243:13 pmGNWForm 8.3 - [BENCHMARK HOLDINGS PLC - 01 03 2024] - (CGAML)
4th Mar 202411:22 amRNSForm 8.5 (EPT/RI) - Benchmark Holdings plc
29th Feb 202411:19 amRNSForm 8.5 (EPT/RI) - Benchmark Holdings Plc
29th Feb 20247:00 amRNSTotal Voting Rights
27th Feb 202411:24 amRNSForm 8.5 (EPT/RI) - Benchmark Holdings Plc
26th Feb 202411:06 amRNSForm 8.5 (EPT/RI) - Benchmark Holdings Plc
23rd Feb 202411:23 amRNSForm 8.5 (EPT/RI) - Benchmark Holdings Plc
22nd Feb 20243:15 pmRNSForm 8.3 - BENCHMARK HOLDINGS PLC
21st Feb 202411:24 amRNSForm 8.5 (EPT/RI) - Benchmark Holdings Plc
20th Feb 202411:40 amRNSForm 8.5 (EPT/RI) - Benchmark Holdings Plc
19th Feb 202410:59 amRNSForm 8.5 (EPT/RI) - Benchmark Holdings Plc
16th Feb 202410:26 amRNSForm 8.5 (EPT/RI) - Benchmark Holdings plc
15th Feb 20247:00 amRNSQ1 Results
14th Feb 202411:37 amRNSForm 8.5 (EPT/RI) - Benchmark Holdings Plc
8th Feb 20244:00 pmRNSResult of AGM
6th Feb 20244:08 pmRNSForm 8.3 - Benchmark Holdings PLC
6th Feb 20247:36 amRNSForm 8.3 - Benchmark Holdings PLC
5th Feb 20245:30 pmRNSRule 2.9 Announcement
5th Feb 20242:50 pmRNSForm 8.3 - Benchmark Holdings PLC
5th Feb 202410:20 amRNSForm 8.5 (EPT/RI) - Benchmark Holdings Plc

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.